Therapeutic Candidate or Device Autologous naïve-stem/memory T cells engineered with a chimeric antigen receptor targeting the HER2 antigen (HER2BBζ-Tn/mem) Indication HER2-positive brain and/or leptomeningeal metastases, primarily from breast cancer Therapeutic…
Therapeutic Candidate or Device A promising immunotherapy utilizing a patient’s memory T cells engineered to express chimeric antigen receptors for targeted tumor killing. Indication Malignant glioma (WHO III and IV),…
Therapeutic Candidate or Device Autologous dendritic cells pulsed with HLA-specific peptides derived from tumor-associated antigens Indication Newly diagnosed glioblastoma Therapeutic Mechanism Autologous dendritic cells charged with peptides derived from tumor-associated…
Therapeutic Candidate or Device Blood stem cells will be genetically engineered to protect them from chemotherapy in glioblastoma patients, producing better patient survival. Indication Patients with newly diagnosed glioblastoma (GBM)…
Karen Aboody speaks at the 2011 CIRM Grantee Meeting about the developing a stem cell-based clinical trial for malignant brain tumors. Dr. Aboody and her team at the City of…
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
